← Leaderboards
Michael Sean Rogers
Boston Children'S Hospital
$7,817,439
Attributed
$8,429,184
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,429,184 · 6
By mechanism
R01$7,725,646 · 4
R21$703,538 · 2
Top collaborators
- Bruce R Zetter3 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsSignal TransductionIn VivoSmall MoleculeReceptorProteinsMediatingExhibitsEndothelial CellsHigh Throughput ScreeningAngiogenesisMalignant NeoplasmsLeadAngiogenesis InhibitorsDesignClinical TrialsBlood CapillariesGrowthMorphogenesisPathway InteractionsPathologyGenerationsBaseArthritis
Grant awards (18)
CMG2 as a target for safe and effective treatment of endometriosis-associate pain$1,128,672
R01 · FY2025 · HD · contact PI
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis$348,502
R01 · FY2025 · EY · contact PI
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis$410,004
R01 · FY2024 · EY · contact PI
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis$410,004
R01 · FY2023 · EY · contact PI
Identification of a Novel Target for the Treatment of Endometriosis-associated Pain$221,250
R21 · FY2023 · HD · contact PI
CMG2 as a target for safe and effective treatment of endometriosis-associate pain$1,758,450
R01 · FY2022 · HD · contact PI
Functional requirement of CMG2 for endothelial cell chemotaxis and resulting angiogenesis$410,000
R01 · FY2022 · EY · contact PI
Identification of a Novel Target for the Treatment of Endometriosis-associated Pain$265,500
R21 · FY2022 · HD · contact PI
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor$396,856
R01 · FY2019 · CA
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor$411,481
R01 · FY2018 · CA
Assays to Identify Prostate Cancer Therapeutics Targeting Antizyme Inhibitor$415,154
R01 · FY2017 · CA
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$443,484
R01 · FY2012 · EY · contact PI
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$414,734
R01 · FY2011 · EY · contact PI
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$361,723
R01 · FY2010 · EY · contact PI
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$69,201
R01 · FY2010 · EY · contact PI
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$365,901
R01 · FY2009 · EY · contact PI
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors$381,480
R01 · FY2008 · EY · contact PI
Assay for Inhibitors of Angiogenesis and Anthrax Toxin Receptor 1$216,788
R21 · FY2007 · NS · contact PI